CR20120139A - Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos - Google Patents

Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos

Info

Publication number
CR20120139A
CR20120139A CR20120139A CR20120139A CR20120139A CR 20120139 A CR20120139 A CR 20120139A CR 20120139 A CR20120139 A CR 20120139A CR 20120139 A CR20120139 A CR 20120139A CR 20120139 A CR20120139 A CR 20120139A
Authority
CR
Costa Rica
Prior art keywords
glycosilation
polypeptides
union
products
involve
Prior art date
Application number
CR20120139A
Other languages
English (en)
Spanish (es)
Inventor
Jochen Huber
Francis Blanche
Tarik Dabdoubi
Fabienne Soubrier
Ingo Focken
Kathrin Heermeier
Jochen Kruip
Crhistian Lange
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09290778A external-priority patent/EP2308896A1/en
Priority claimed from EP09290845A external-priority patent/EP2319871A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20120139A publication Critical patent/CR20120139A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
CR20120139A 2009-10-09 2012-03-22 Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos CR20120139A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290778A EP2308896A1 (en) 2009-10-09 2009-10-09 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP09290845A EP2319871A1 (en) 2009-11-05 2009-11-05 Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same

Publications (1)

Publication Number Publication Date
CR20120139A true CR20120139A (es) 2012-07-13

Family

ID=43448431

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120139A CR20120139A (es) 2009-10-09 2012-03-22 Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos

Country Status (20)

Country Link
US (1) US20120282637A1 (enExample)
EP (1) EP2486058A1 (enExample)
JP (1) JP2013507115A (enExample)
KR (1) KR20120089863A (enExample)
CN (1) CN102686611A (enExample)
AU (1) AU2010305374A1 (enExample)
BR (1) BR112012007821A2 (enExample)
CA (1) CA2777237A1 (enExample)
CL (1) CL2012000886A1 (enExample)
CR (1) CR20120139A (enExample)
EC (1) ECSP12011787A (enExample)
IL (1) IL218968A0 (enExample)
MA (1) MA33661B1 (enExample)
MX (1) MX2012004090A (enExample)
PE (1) PE20121689A1 (enExample)
PH (1) PH12012500564A1 (enExample)
RU (1) RU2558301C2 (enExample)
TN (1) TN2012000138A1 (enExample)
WO (1) WO2011042548A1 (enExample)
ZA (1) ZA201202099B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
GB201200563D0 (en) * 2012-01-13 2012-02-29 Imp Innovations Ltd Binding molecule
WO2014167826A1 (ja) * 2013-04-08 2014-10-16 株式会社免疫生物研究所 アミロイド前駆体タンパク質のα－セクレターゼ切断後のＣ末端側断片の切断面を特異的に認識する抗体及びその利用
WO2014197460A1 (en) * 2013-06-04 2014-12-11 The Trustees Of The University Of Pennsylvania Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies
LT3038650T (lt) 2013-08-30 2021-09-10 Immunogen, Inc. Antikūnai ir foliatų receptoriaus 1 nustatymo testai
EP3633381A3 (en) 2013-12-05 2020-07-29 The Broad Institute, Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
EP3207062A1 (en) * 2014-10-16 2017-08-23 The Broad Institute Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
JP6679096B2 (ja) * 2014-10-21 2020-04-15 学校法人 久留米大学 Ｒａｇｅアプタマーおよびその用途
EP3223865A4 (en) * 2014-10-31 2018-10-03 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4
ES2956662T3 (es) * 2015-05-12 2023-12-26 Syntimmune Inc Anticuerpos anti-FcRn humanizados con afinidad madurada
WO2016187354A1 (en) 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
JP6913030B2 (ja) 2015-05-18 2021-08-04 アジェンシス，インコーポレイテッド Ａｘｌタンパク質に結合する抗体
WO2016201319A1 (en) * 2015-06-10 2016-12-15 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
WO2016201368A1 (en) 2015-06-10 2016-12-15 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
JP6578595B2 (ja) * 2015-08-28 2019-09-25 国立研究開発法人科学技術振興機構 抗アセチル化ヒストンｈ４抗体
EP3381941B1 (en) * 2015-09-08 2020-11-11 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. THERAPEUTIC COMBINATIONS WITH ANTI-FOLR1 IMMUNOCONJUGATES
WO2017106196A1 (en) 2015-12-14 2017-06-22 The Broad Institute, Inc. Compositions and methods for treating cardiac dysfunction
CN108570106B (zh) * 2017-03-10 2021-07-16 北京天广实生物技术股份有限公司 抗埃博拉病毒单克隆抗体、其制备方法及用途
EP3661965A4 (en) * 2017-08-02 2022-07-13 Phanes Therapeutics, Inc. ANTI-CD47 ANTIBODIES AND USES THEREOF
CA3096222A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
JP2022539178A (ja) * 2019-06-26 2022-09-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｉｌ１ｒａｐ結合タンパク質
JP7701913B2 (ja) 2019-10-03 2025-07-02 エータイアー ファーマ， インコーポレイテッド 抗ｎｒｐ２抗体を含む組成物および方法
WO2022019924A1 (en) * 2020-07-23 2022-01-27 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
CN113956363B (zh) * 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
EP4433514A4 (en) * 2021-11-18 2025-10-08 Salavarx Llc ANTIBODIES TO THE ADVANCED GLYCATION ENDPRODUCT RECEPTOR AND THEIR USES
CN116554311B (zh) * 2023-05-04 2023-11-21 中国人民解放军军事科学院军事医学研究院 抗CD2v-N的特异性抗体及其应用
KR20250001879A (ko) 2023-06-28 2025-01-07 주식회사 세바바이오텍 완도호랑가시나무와 노루궁뎅이버섯 추출물을 유효성분으로 포함하는 최종당화산물 억제용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
ZA988461B (en) * 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
WO2002013857A2 (en) 2000-08-17 2002-02-21 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AU2002320762B2 (en) 2001-05-21 2006-09-21 Intercell Ag Immunostimulatory oligodeoxynucleic molecules
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
CA2645125A1 (en) * 2006-03-02 2007-09-13 Oncotherapy Science, Inc. Methods for diagnosing pancreatic cancer using reg4 protein
US20070286858A1 (en) * 2006-03-21 2007-12-13 Wyeth Methods and Compositions for Antagonism of RAGE
CN101405300A (zh) * 2006-03-21 2009-04-08 惠氏公司 用于拮抗rage的方法及组合物
US20090182127A1 (en) * 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
CN100586960C (zh) * 2006-06-23 2010-02-03 陈志南 HAb18GC2单抗和其轻、重链可变区基因及应用
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
KR101649189B1 (ko) * 2008-05-09 2016-08-18 애브비 인코포레이티드 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도

Also Published As

Publication number Publication date
ZA201202099B (en) 2012-11-28
MX2012004090A (es) 2012-04-20
ECSP12011787A (es) 2012-10-30
AU2010305374A1 (en) 2012-05-03
RU2012118598A (ru) 2013-11-20
CN102686611A (zh) 2012-09-19
EP2486058A1 (en) 2012-08-15
PH12012500564A1 (en) 2012-10-22
RU2558301C2 (ru) 2015-07-27
JP2013507115A (ja) 2013-03-04
IL218968A0 (en) 2012-07-31
PE20121689A1 (es) 2012-12-14
CL2012000886A1 (es) 2012-12-14
WO2011042548A1 (en) 2011-04-14
US20120282637A1 (en) 2012-11-08
BR112012007821A2 (pt) 2017-05-30
CA2777237A1 (en) 2011-04-14
MA33661B1 (fr) 2012-10-01
TN2012000138A1 (en) 2013-09-19
KR20120089863A (ko) 2012-08-14

Similar Documents

Publication Publication Date Title
CR20120139A (es) Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos
GT201300295A (es) "composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales"
IN2012MN02923A (enExample)
CO7131365A2 (es) Factores de coagulación de acción prolongada y métodos de producción de los mismos
HK1202067A1 (en) Therapeutic agents comprising insulin amino acid sequences
DOP2010000229A (es) Compuestos que comprenden un grupo ciclobutoxi
PH12015502524A1 (en) New somatostatin receptor subtype 4 (sstr4) agonists
CO6290770A2 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
MY180672A (en) Ace2 polypeptide
JO3172B1 (ar) تركيبة وطريقة وتحضير الصفراء الصناعية
MX2011011797A (es) Fenilureas y fenilamidas sustituidas como ligandos del receptor de vanilloides.
IN2012DN02652A (enExample)
BR112013031268A8 (pt) polipeptídeos
PH12012500572A1 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
IN2015KN00262A (enExample)
PH12019500171A1 (en) Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators
GB2516403A (en) Fibrous structures and methods for making same
MX344248B (es) Metodos de purificacion de polipeptidos.
BR112012027545A8 (pt) Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
WO2015022575A3 (en) A process for the preparation of gc-c agonist
IN2012DN02488A (enExample)
JO2857B1 (en) Vinyl pipers with modified activity of tumor-resistant TNF
WO2010127246A3 (en) Hnf4 modulators and methods of use
MX2010011055A (es) Derivados peptidicos de opiorfina como potentes inhibidores de ectopeptidasas degradadoras de encefalinas.